About AML

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. When someone has AML, it means the bone marrow may make abnormal white blood cells, red blood cells, or platelets.

These abnormal cells are called leukemia cells or blasts. Leukemia is monitored by measuring the amount of blasts. As the percentage of leukemia cells increases, the bone marrow is less able to create normal white and red blood cells and platelets.

Bone marrow from healthy patient

Bone marrow from healthy patient

Bone marrow from patient with AML

Bone marrow from patient with AML

What is VYXEOS?

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.

Important Safety Information